H.C. Wainwright analyst Andrew Fein raised the firm’s price target on PepGen (PEPG) to $20 from $18 and keeps a Buy rating on the shares. A new U.S. composition of matter patent for PGN-EDODM1 securing exclusivity into the 2040s reinforces the durability of its myotonic dystrophy type 1 franchise, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEPG: